• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    AVITA Medical Announces TGA Certification in Australia and Medsafe WAND Listing in New Zealand for RECELL GO

    4/29/26 4:05:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care
    Get the next $RCEL alert in real time by email
    • RECELL GO® receives regulatory clearance in Australia and New Zealand, enabling commercialization across both markets

    • RECELL GO is AVITA Medical's next-generation system that automates and standardizes the preparation of RECELL® Spray-On Skin™ for the treatment of burn and trauma wounds



    VALENCIA, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, today announced that RECELL GO, its next-generation system for preparing RECELL Spray-On Skin, has received certification from Australia's Therapeutic Goods Administration ("TGA") and has been listed on New Zealand's Web Assisted Notification of Devices ("WAND") database by Medsafe, enabling commercialization in both markets for burn and acute wound treatment.

    AVITA Medical's exclusive distribution partner in Australia and New Zealand, Revolution Surgical Pty Ltd ("Revolution Surgical"), expects to initiate commercial launch within the coming weeks.

    Professor Fiona Wood, Director of the Burns Service of Western Australia and Director of the Burn Injury Research Unit at the University of Western Australia, commented: "RECELL GO represents the evolution of a technology we developed in Australia, building on our original approach by eliminating manual preparation steps and reducing the burden on clinical teams. Its certification is significant in expanding RECELL access for burn and trauma patients across Australia and New Zealand."

    "The TGA certification and WAND listing of RECELL GO represents an important step in expanding access to RECELL," said Cary Vance, Interim Chief Executive Officer of AVITA Medical. "With RECELL GO, we are bringing greater standardization and efficiency to the preparation process, and together with our partner Revolution Surgical, we look forward to supporting adoption across Australia and New Zealand."

    About RECELL GO

    RECELL GO combines a reusable, AC-powered RECELL Processing Device ("RPD") with a single-use RECELL Preparation Kit ("RPK"), with one RPK capable of treating wounds up to 1,920 cm2.

    In Australia, RECELL has historically been prepared using a manual process. RECELL GO precisely regulates enzyme incubation times and processing conditions, helping to optimize cell yield and viability while reducing operator variability, training burden, and operating room complexity.

    RECELL works by using a small sample of a patient's own healthy skin to prepare a suspension of skin cells that is sprayed onto the wound. This approach can promote faster wound healing while reducing the need for large skin grafts – lowering donor-site pain and scarring – and shortening hospital stays.

    RECELL was originally developed in Australia by renowned burn surgeon Professor Fiona Wood, who was recently awarded the Lifetime Achievement Award by the American Burn Association ("ABA") at the ABA's 2026 Annual Meeting. RECELL GO represents the evolution of that innovation into a standardized, device-enabled system that is now approved for use in the U.S., Europe, the U.K., Australia and New Zealand.

    About AVITA Medical, Inc.

    AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is RECELL®, approved by the FDA for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient's own skin to create Spray-On Skin™, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to market, sell, and distribute Cohealyx®, an AVITA Medical-branded collagen-based dermal matrix, and the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix.

    In international markets, RECELL is approved to promote skin healing in a wide range of applications, including thermal burn and trauma wounds. RECELL and RECELL GO® are CE-marked in Europe and have TGA certification in Australia and are listed with Medsafe in New Zealand; RECELL is PMDA-approved in Japan.

    To learn more, visit www.avitamedical.com.

    CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

    This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements generally may be identified by the use of words such as "anticipate," "could," "expect," "may," and similar words or expressions, and the use of future dates. Forward-looking statements include, but are not limited to, statements relating to the timing and realization of regulatory approvals of our products; anticipated market share growth and revenue generation; failure to achieve the anticipated benefits from approval of our products; risks associated with international operations and expansion; and other business effects, including the effects of industry, as well as other economic or political conditions outside of the Company's control. These statements are made as of the date of this press release, and the Company undertakes no obligation to publicly update or revise any of these statements, except as required by law. For additional information and other important factors that may cause actual results to differ materially from forward-looking statements, please see the "Risk Factors" section of the Company's latest Annual Report on Form 10-K and other publicly available filings for a discussion of these and other risks and uncertainties.

    Investor & Media Contact:

    Ben Atkins

    Phone +1-805 341 1571

    investor@avitamedical.com | media@avitamedical.com

    Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.

    ©2026 AVITA Medical. AVITA Medical®, Cohealyx®, RECELL®, RECELL GO®, and Spray-On Skin™ are trademarks of AVITA Medical. PermeaDerm® is a registered trademark of Stedical Scientific, Inc. All other trademarks are the properties of their respective owners.



    Primary Logo

    Get the next $RCEL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RCEL

    DatePrice TargetRatingAnalyst
    5/15/2026$6.00Hold → Buy
    Lake Street
    3/5/2026$10.00Outperform
    Northland Capital
    11/20/2025Sell → Neutral
    BTIG Research
    8/8/2025$3.00Neutral → Sell
    BTIG Research
    12/24/2024$25.00Buy
    D. Boral Capital
    4/11/2024Buy → Neutral
    BTIG Research
    6/27/2023$23.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $RCEL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AVITA Medical to Host Investor Webinar Briefing

    VALENCIA, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, President and Chief Executive Officer, and David O'Toole, Chief Financial Officer, on May 20, 2026, at 4:00 p.m. Pacific Time (May 21, 2026, at 9:00 a.m. Australian Eastern Standard Time). The webinar presentation will cover financial and business results from AVITA Medical's recent first quarter 2026 earnings webcast and will conclude with a Q&A session. Participants are invited to submit thei

    5/17/26 6:00:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    AVITA Medical Reports First Quarter 2026 Financial Results

    VALENCIA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions ("AVITA Medical," or the "Company"), today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights and Recent Business Updates Total revenue of approximately $19.3 million, up 4% year-over-year and approximately 10% sequentially, driven by contributions from Cohealyx® and improved RECELL® utilization as reimbursement dynamics normalizeAppointment of Cary Vance as President and Chief Executive Officer following a comprehensive search process led by a specia

    5/14/26 4:05:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    AVITA Medical Names Cary Vance as Chief Executive Officer

    Board appoints Cary Vance as President and Chief Executive Officer Follows successful interim tenure and thorough search process by the Board Jan Stern Reed elected as Chair of the AVITA Medical Board VALENCIA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company, today announced that its Board of Directors has appointed Cary Vance as President and Chief Executive Officer, effective immediately. The Board of Directors has also appointed Jan Stern Reed as its Chair, effective immediately. Mr. Vance, who has served as Interim CEO since October 2025, will continue to serve on the Board as an executive member.

    4/30/26 8:50:00 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $RCEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Avita Medical upgraded by Lake Street with a new price target

    Lake Street upgraded Avita Medical from Hold to Buy and set a new price target of $6.00

    5/15/26 7:56:04 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    Northland Capital initiated coverage on Avita Medical with a new price target

    Northland Capital initiated coverage of Avita Medical with a rating of Outperform and set a new price target of $10.00

    3/5/26 8:30:26 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    Avita Medical upgraded by BTIG Research

    BTIG Research upgraded Avita Medical from Sell to Neutral

    11/20/25 7:57:06 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $RCEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mcnamara Robert was granted 22,214 shares, increasing direct ownership by 26% to 108,985 units (SEC Form 4)

    4 - AVITA Medical, Inc. (0001762303) (Issuer)

    6/4/26 7:39:08 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    Director Woody Joseph Fralin was granted 62,761 shares, increasing direct ownership by 314% to 82,761 units (SEC Form 4)

    4 - AVITA Medical, Inc. (0001762303) (Issuer)

    6/4/26 7:10:02 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    Director Tarnoff Michael E was granted 48,464 shares (SEC Form 4)

    4 - AVITA Medical, Inc. (0001762303) (Issuer)

    6/4/26 7:09:40 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $RCEL
    Leadership Updates

    Live Leadership Updates

    View All

    AVITA Medical Announces Changes to its Board of Directors

    Veteran healthcare executive Joe Woody joins the BoardLou Panaccio retires after over a decade of service VALENCIA, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. ((ASX: AVH, NASDAQ:RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced the appointment of Joe Woody as a new non-executive Director and the retirement of Lou Panaccio, who served as Chairman from July 2014 to August 2025. "We are pleased to welcome Joe to the Board. His extensive track record leading global med-tech companies and driving commercial excellence will be invaluable as we continue to scale AVITA Medical's growth," said Cary Vance, Interim CEO of

    1/5/26 4:05:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    AVITA Medical Announces CEO Transition

    Board Chairman Cary Vance appointed Interim CEOBoard member Jan Stern Reed appointed Lead Independent DirectorThird quarter 2025 preliminary revenue expected to be approximately $17 million VALENCIA, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)) ("AVITA Medical", or the "Company"), a leading therapeutic acute wound care company, today announced that the Board of Directors has named Chairman of the Board Cary Vance as Interim Chief Executive Officer, effective immediately. In conjunction with this appointment, Jim Corbett is leaving his positions as CEO and member of the Board. Mr. Vance will continue to serve as Chairman of the Board, while Board m

    10/16/25 6:15:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    AVITA Medical Announces Appointment of Michael Tarnoff, MD, FACS, to its Board of Directors and Transition of Board Chair Role to Cary Vance

    Dr. Tarnoff brings extensive executive and medical leadership experience from various organizations, including Tufts Medical Center and Medtronic.The Board thanks Lou Panaccio, its long-standing Board Chair, for his service as he steps down and Cary Vance assumes the Chair position. VALENCIA, Calif. and MELBOURNE, Australia, Aug. 06, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, announced today the appointment to its Board of Directors (the "Board") of Michael Tarnoff, MD, FACS, as a non-executive Director, effective August 6, 2025. Dr. Tarnoff's appointment comes as the Company fu

    8/6/25 4:05:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $RCEL
    Financials

    Live finance-specific insights

    View All

    AVITA Medical Reports First Quarter 2026 Financial Results

    VALENCIA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions ("AVITA Medical," or the "Company"), today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights and Recent Business Updates Total revenue of approximately $19.3 million, up 4% year-over-year and approximately 10% sequentially, driven by contributions from Cohealyx® and improved RECELL® utilization as reimbursement dynamics normalizeAppointment of Cary Vance as President and Chief Executive Officer following a comprehensive search process led by a specia

    5/14/26 4:05:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    AVITA Medical Names Cary Vance as Chief Executive Officer

    Board appoints Cary Vance as President and Chief Executive Officer Follows successful interim tenure and thorough search process by the Board Jan Stern Reed elected as Chair of the AVITA Medical Board VALENCIA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company, today announced that its Board of Directors has appointed Cary Vance as President and Chief Executive Officer, effective immediately. The Board of Directors has also appointed Jan Stern Reed as its Chair, effective immediately. Mr. Vance, who has served as Interim CEO since October 2025, will continue to serve on the Board as an executive member.

    4/30/26 8:50:00 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    AVITA Medical to Announce First Quarter 2026 Financial Results

    VALENCIA, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company, today announced that it will report its first quarter 2026 financial results after the close of the U.S. financial markets on Thursday, May 14, 2026. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, May 15, 2026, at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent business highlights. First Quarter 2026 Webcast and Conference Call InformationTo listen to the conference call webcast, please register and join using the following link: https://edge.media-serve

    4/23/26 4:10:00 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $RCEL
    SEC Filings

    View All

    SEC Form 10-Q filed by Avita Medical Inc.

    10-Q - AVITA Medical, Inc. (0001762303) (Filer)

    5/14/26 4:20:41 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    Avita Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AVITA Medical, Inc. (0001762303) (Filer)

    5/14/26 4:10:17 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    Avita Medical Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - AVITA Medical, Inc. (0001762303) (Filer)

    5/1/26 4:54:15 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $RCEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Woody Joseph Fralin bought $84,936 worth of shares (20,000 units at $4.25) (SEC Form 4)

    4 - AVITA Medical, Inc. (0001762303) (Issuer)

    6/3/26 4:30:16 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    CFO O'Toole David D bought $8,520 worth of shares (2,000 units at $4.26), increasing direct ownership by 1% to 145,927 units (SEC Form 4)

    4 - AVITA Medical, Inc. (0001762303) (Issuer)

    5/20/26 4:30:06 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    CFO O'Toole David D bought $8,480 worth of shares (2,000 units at $4.24), increasing direct ownership by 1% to 143,927 units (SEC Form 4)

    4 - AVITA Medical, Inc. (0001762303) (Issuer)

    5/19/26 4:30:02 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    $RCEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Avita Medical Inc.

    SC 13G - AVITA Medical, Inc. (0001762303) (Subject)

    2/13/24 4:58:57 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Avita Medical Inc.

    SC 13G - AVITA Medical, Inc. (0001762303) (Subject)

    1/26/24 4:23:41 PM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Avita Medical Inc. (Amendment)

    SC 13G/A - AVITA Medical, Inc. (0001762303) (Subject)

    2/9/23 11:07:47 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care